Development of a flow cytometric method to detect the presence of mutated nucleophosmin 1 in acute myeloid leukemia
Hematology/Oncology and Stem Cell Therapy · 2015-07 · 8 (3) · 106-114
DOI: 10.1016/j.hemonc.2015.06.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematology/Oncology and Stem Cell Therapy, 2015-07. Verfasst von Louis Almero Du Pisani und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Haematology, Department of Clinical laboratory Sciences, University of Cape Town, South Africa; National Health Laboratory Services/Groot…. Hauptthemen laut MEDLINE: Mutation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Health Laboratory Service Research Trust.
Abstract (Originalsprache)
OBJECTIVE/BACKGROUND: Nucleophosmin 1 (NPM1) plays multiple roles in cell growth and proliferation. Deletion/insertion mutations in exon 12 of NPM1 ( NPM1-DIM ), commonly found in patients with acute myeloid leukemia (AML), alter the C-terminal amino acids and disrupt the normal nucleocytoplasmic shuttling function of the protein, which in turn leads to disease pathogenesis. However, this altered function as a result of NPM1-DIM positivity is actually associated with a significantly better response to therapy and overall survival, and thus it is of clinical relevance to investigate the mutation status at diagnosis. Our objective was to design a reliable flow cytometry assay to detect mutated NPM1 in peripheral blood (PB) samples from AML patients, using a polyclonal mutation-specific antibody. METHODS: A commercially available NPM1 mutation-specific polyclonal antibody in combination with a secondary goat antirabbit antibody was used to detect the C-terminal-mutated NPM1 by flow cytometry. OCI/AML3 (+) cell line and clinical PB controls were used to optimize the assay and determine sensitivity, reliability, and reproducibility parameters. The assay was then tested on a small cohort of 12 AML patients at diagnosis and compared with NPM1-DIM testing on a standard polymerase chain reaction (PCR) platform. RESULTS: Flow cytometry using the polyclonal antibody was able to reliably detect mutated NPM1 populations of at least 10%. Using an objective analysis of the mean fluorescent intensity, clear positive and negative mutated cell populations could be distinguished using the clinical AML samples. From the analysis of 12 patients, 2 were found to be positive using this assay, which corresponded with conventional PCR methodology. CONCLUSIONS: Flow cytometry may be used to detect NPM1 C-terminal mutations in AML patients using a polyclonal anti-NPM1 antibody, allowing rapid mutation status determination at diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Haematology, Department of Clinical laboratory Sciences, University of Cape Town, South Africa; National Health Laboratory Services/Groote Schuur Hospital, Haematology, Cape Town, South Africa.
- Division of Haematology, Department of Clinical laboratory Sciences, University of Cape Town, South Africa; National Health Laboratory Services/Groote Schuur Hospital, Haematology, Cape Town, South Africa. Electronic ad…
Förderung
- National Health Laboratory Service Research Trust
Zitieren
APA
Du Pisani, L. A., & Shires, K. (2015). Development of a flow cytometric method to detect the presence of mutated nucleophosmin 1 in acute myeloid leukemia. Hematology/Oncology and Stem Cell Therapy, 8(3), 106-114. https://doi.org/10.1016/j.hemonc.2015.06.009
Vancouver
Du Pisani LA, Shires K. Development of a flow cytometric method to detect the presence of mutated nucleophosmin 1 in acute myeloid leukemia. Hematology/Oncology and Stem Cell Therapy. 2015;8(3):106-114. doi:10.1016/j.hemonc.2015.06.009
BibTeX
@article{DuPisani2015,
author = {Du Pisani, Louis Almero and Shires, Karen},
title = {Development of a flow cytometric method to detect the presence of mutated nucleophosmin 1 in acute myeloid leukemia},
journal = {Hematology/Oncology and Stem Cell Therapy},
year = {2015},
volume = {8},
number = {3},
pages = {106--114},
doi = {10.1016/j.hemonc.2015.06.009}
}
EUVIMED